The Latest Cardiac and Vascular News
NEW YORK and MELBOURNE, Australia, Aug. 29, 2019 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today reported strong operational progress and financial highlights for the fourth quarter and full-year ended June 30, 2019 (FY2019). Mesoblast Chief Executive Dr Silviu Itescu stated: “The Company is well positioned to deliver substantial shareholder value in the […]
WASHINGTON, June 24, 2019 /PRNewswire/ — The Centers for Medicaid and Medicare Services last Friday issued their final National Coverage Decision on how hospitals will be approved to do the TAVR (transaortic valve replacement) procedure, a less invasive valve replacement treatment that avoids open heart surgery and allows patients to resume daily life more quickly. “CMS’s decision to […]
NEW YORK and MELBOURNE, Australia, March 26, 2019 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in cellular medicines for inflammatory diseases, today announced that the International Center for Health Outcomes and Innovation Research (InCHOIR) at the Icahn School of Medicine at Mount Sinai and Mesoblast have entered into a Memorandum of Understanding (MOU) […]
NEW YORK and MELBOURNE, Australia, Feb. 19, 2019 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a world leader in development and commercialization of cellular medicines, announced today that the last patient has now been dosed in the Phase 3 events-driven trial of its allogeneic cell therapy product candidate Revascor for advanced chronic heart failure. The 566-patient trial […]
NEW YORK and MELBOURNE, Australia, Feb. 13, 2019 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB) will report financial results for the half year and second quarter ended December 31, 2018 in a webcast beginning at 4:30pm on Wednesday, February 20, 2019 EST; 8:30am Thursday, February 21, 2019 AEDT. The live webcast can be accessed via https://webcasting.boardroom.media/broadcast/5c6107137e5a7b7d6e8941e4 […]
NEW YORK and MELBOURNE, Australia, Jan. 14, 2019 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX: MSB; Nasdaq: MESO) today announced that it has drawn down a further US$15 million from its US$75 million, non-dilutive, four-year credit facility with Hercules Capital, Inc. (NYSE:HTGC). The funds will be used primarily to ramp up Mesoblast’s product commercialization programs including […]
NEW YORK and MELBOURNE, Australia, Jan. 07, 2019 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), world leader in development and commercialization of allogeneic (off-the-shelf) cellular medicines, today announced that it has completed patient recruitment in the events-driven Phase 3 trial of its product candidate Revascor (MPC-150-IM) for advanced chronic heart failure. Mesoblast Chief Executive Dr Silviu Itescu stated: […]
NEW YORK and MELBOURNE, Australia, Dec. 28, 2018 (GLOBE NEWSWIRE) — Mesoblast will enter 2019 with the most mature cell therapy product pipeline and technology platform in the regenerative medicine industry. Two commercial products have already been approved and marketed by the Company’s licensees JCR Pharmaceuticals Co, Ltd. in Japan and Takeda Pharmaceutical Company in Europe. […]
MELBOURNE, Australia and NEW YORK, Nov. 15, 2018 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today reported strong financial results and provided operational highlights for the first quarter ended September 30, 2018. Key financial results for the three months ended September 30, 2018 (first quarter FY2019) Significant increase in revenues to US$11.6 million in the first […]
NEW YORK and MELBOURNE, Australia, Oct. 02, 2018 (GLOBE NEWSWIRE) — Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that the 159-patient randomized placebo-controlled Phase 2b trial evaluating its allogeneic mesenchymal precursor cell (MPC) product candidate MPC-150-IM in the treatment of end-stage heart failure patients implanted with a left ventricular assist device (LVAD) has been selected as a late-breaking […]
